DexCom (DXCM), a prominent player in the glucose monitoring market, reported first-quarter fiscal 2011 loss per share of 19 cents, a penny higher than the Zacks Consensus Estimate while sharply less than the year-ago loss of 40 cents per share. Net loss for the quarter trimmed roughly 41.5% year over year to $11.9 million owing to a healthy revenue growth.
Revenues
Revenues for the quarter shot up roughly 48.5% year over year to $14.2 million, still missing the Zacks Consensus Estimate of $15 million. Product sales almost doubled year over year to $13.1 million while development grant and other revenues dropped 62.8% to slightly over $1 million.
Margins and Expenses
Gross margin for the quarter dipped slightly to 36.1% from 36.2% a year ago. Operating expenses leaped 16.9% year over year to $17 million, partly on account of higher R&D spending, which surged 32.3% to $6.3 million.
Balance Sheet
DexCom exited the quarter with cash and short-term marketable securities of $37.3 million, down 25.2% year over year. The company de-leveraged its balance sheet as long-term debt (inclusive of current portion) declined to $0.3 million at the end of the quarter from $5.9 million a year ago. Accumulated deficit climbed 3.4% year over year to $358.2 million, as of March 31, 2011.
Outlook
DexCom has not provided any financial forecasts for fiscal 2011. We believe the company is poised to gain a major share of the glucose monitoring market driven by sustained product development initiatives, collaborations, favorable reimbursement coverage and increased need for continuous glucose monitoring.
However, we remain concerned about aggressive competition from much larger players such as Johnson & Johnson (JNJ), Medtronic (MDT) and Abbott (ABT), and a stricter regulatory environment. We currently have a long-term Neutral recommendation on DexCom.
ABBOTT LABS (ABT): Free Stock Analysis Report
DEXCOM INC (DXCM): Free Stock Analysis Report
JOHNSON & JOHNS (JNJ): Free Stock Analysis Report
Be the first to comment